B
SPRB

Bailard’s Spruce Biosciences SPRB Stock Holding History

Bailard’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-282
Closed -$29K – 795
2022
Q3 		$29K Buy
+282
New +$39.4K ﹤0.01% 656

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Bailard's SPRB Position: Q4 2022 in Review

Bailard sold out of Spruce Biosciences (SPRB) in Q4 2022, closing a stake of 282 shares — an estimated $29K sold.

Bailard first reported a position in SPRB in Q3 2022 and held it in 1 quarter. The position peaked at $29K in Q3 2022. 29 funds tracked by Wall St. Rank hold SPRB as of Q4 2022.

  • Bailard reported no remaining Spruce Biosciences position as of Q4 2022 after selling out during the quarter.
  • Bailard sold 282 Spruce Biosciences shares in Q4 2022, an estimated $29K.
  • Bailard first reported a position in Spruce Biosciences in Q3 2022 and held it in 1 quarter.
  • Bailard's Spruce Biosciences position peaked at $29K in Q3 2022.
  • 29 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.